From the helm: Alterity Therapeutics (ASX:ATH), CEO, David Stamler.

In this episode of From the Helm, Grady chats with Alterity Therapeutics (ASX:ATH) CEO David Stamler, to discuss their neurodegenerative disorder treatment specifically targeting Multiple System Atrophy (MSA), a rare and aggressive disease affecting involuntary functions and motor control. Find Bell Direct here: Twitter: https://twitter.com/belldirect Facebook: https://www.facebook.com/BellDirectAu... LinkedIn: https://www.linkedin.com/company/bell... Instagram: https://www.instagram.com/bell.direct/ Threads: https://www.threads.net/@bell.direct